Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Illumina
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:businessModel |
private
|
| gptkbp:CEO |
gptkb:Bob_Ragusa
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
liquid biopsy
early cancer detection |
| gptkbp:founded |
2016
|
| gptkbp:founder |
gptkb:Illumina
|
| gptkbp:headquarters_location |
gptkb:Menlo_Park,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Grail (company)
|
| gptkbp:industry |
gptkb:biotechnology
healthcare |
| gptkbp:notableInvestment |
gptkb:Amazon
gptkb:Bill_Gates gptkb:Jeff_Bezos gptkb:Illumina gptkb:Arch_Venture_Partners gptkb:Johnson_&_Johnson_Innovation |
| gptkbp:numberOfEmployees |
over 700 (as of 2023)
|
| gptkbp:parentCompany |
gptkb:Illumina
|
| gptkbp:product |
gptkb:Galleri
|
| gptkbp:regulatory_challenge |
European Commission antitrust review
FTC lawsuit over Illumina acquisition |
| gptkbp:specializesIn |
multi-cancer early detection tests
|
| gptkbp:website |
https://grail.com
|
| gptkbp:bfsParent |
gptkb:Samir_Kaul
|
| gptkbp:bfsLayer |
6
|